share_log

Bristol-Myers Squibb | 4: Statement of changes in beneficial ownership of securities-Officer Elkins David V

SEC announcement ·  Mar 13 05:48
Summary by Futu AI
On March 10, 2024, David V Elkins, EVP and Chief Financial Officer of Bristol-Myers Squibb (BMY), completed a series of transactions involving the company's common stock. Elkins exercised options to acquire a total of 64,326 shares at no cost. Concurrently, he disposed of 37,970 shares through various means, including the payment of exercise price or tax liability, with some transactions priced at $53.79 per share. The total market value of the disposed shares amounted to $996,298.38. Following these transactions, Elkins directly held 194,968 shares of Bristol-Myers Squibb. Additionally, he indirectly held 215.72 shares through the BMS Savings and Investment Program.
On March 10, 2024, David V Elkins, EVP and Chief Financial Officer of Bristol-Myers Squibb (BMY), completed a series of transactions involving the company's common stock. Elkins exercised options to acquire a total of 64,326 shares at no cost. Concurrently, he disposed of 37,970 shares through various means, including the payment of exercise price or tax liability, with some transactions priced at $53.79 per share. The total market value of the disposed shares amounted to $996,298.38. Following these transactions, Elkins directly held 194,968 shares of Bristol-Myers Squibb. Additionally, he indirectly held 215.72 shares through the BMS Savings and Investment Program.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.